A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of Extended-release (ER) Niacin/Laropiprant in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia.

NCT00479388 Phase 3 COMPLETED Results posted

This is a 12-Week clinical trial in patients with Primary hypercholesterolemia or mixed dyslipidemia to study the effects of ER niacin/laropiprant on lipids.

Details

Lead sponsor	Merck Sharp & Dohme LLC
Phase	Phase 3
Status	COMPLETED
Enrolment	1216
Start date	2007-07
Completion	2008-10

Conditions

• Primary Hypercholesterolemia
• Mixed Dyslipidemia

Interventions

• Comparator: simvastatin
• niacin (+) laropiprant
• Comparator: atorvastatin calcium

Primary outcomes

• Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12 — Baseline and 12 Weeks